News Release
2023.06.14
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
News Release
2022.12.21
Establishment of In-House Facility and Acquisition of License for Packaging, Labeling and Storage of Regenerative Medicine Products
News Release
2022.11.29
Joint Research Agreement for SB623 Targeting Alzheimer’s-Type Dementia
News Release
2022.10.20
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2022.08.01
Notice regarding appointment of new corporate officers
News Release
2022.07.22
Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2022.07.01
Keizo Nakada to Join SanBio as Corporate Officer and Head of Production
News Release
2022.06.01
Andrew Liu to Join SanBio as Chief Strategy Officer
News Release
2022.05.09
Notice of Patent Acquisition for R-SAT, a Distribution Management and Administration Schedule Support System for Regenerative Medicine Products, Jointly Developed with Suzuken Co., Ltd.
News Release
2024.09.05
Positive Results of Key Development Product SB623 for Chronic Effects of Traumatic Brain Injury, including Sustained Motor Function Improvement up to 48 weeks, published in Neurology
News Release
2024.07.31
SanBio Obtains Marketing Approval for “AKUUGO🄬 Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)
News Release
2024.07.29
Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US
News Release
2024.07.10
[Results of Basic Research] Publication of an Article on the Neuronal Activity and Network Formation Promotion of the Key Development Product SB623
News Release
2024.06.20
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.06.12
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.03.26
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2024.03.18
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2023.12.14
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
News Release
2023.08.31
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Media
2022.04.08
On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.
Media
2018.04.20
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
Info
2018.12.27
【Announcement】SanBio will present at the 37th Annual J.P. Morgan Healthcare Conference
Info
2018.08.28
【Announcement】SanBio will be featured on NHK WORLD – JAPAN “Medical Frontiers – The Brain Can Be Regenerated” on September 4 (Tue) 4 times a day, Japan timeIt is available for watching on the Internet.
Info
2018.01.10
SanBio presented at the 36th Annual J.P. Morgan Healthcare Conference
Info
2017.11.22
Keita Mori, CEO of SanBio will speak at 2017 World Alliance Forum in San Francisco on November30
Info
2017.11.22
SanBio will present at 2nd DIA Cell Therapy Products Symposium in Japan on December 15"Quality of Regenerative Medical Products -What do we need to start a clinical study in Japan? -" Takehiko Kaneko, Medical Director & Head of Clinical Development Japan, SanBio Co., Ltd.
Info
2017.05.10
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio will speak at the 7th Annual Traumatic Brain Injury Conference on May 24&25, 2017, Washington DCDr. Bates will be presenting at the 2017 Conference on the subject of San-Bio’s upcoming STEMTRA trial in TBI. Dr. Bates will also participate in the panel session called Milestones and Existing Challenges in Preclinical and Clinical Development of TBI Therapeutics.